Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Ep. 102: Global TB Diagnostics, Part 2 – Dr. Peter Small

Ep. 102: Global TB Diagnostics, Part 2 – Dr. Peter Small

FromHalteres Presents


Ep. 102: Global TB Diagnostics, Part 2 – Dr. Peter Small

FromHalteres Presents

ratings:
Length:
37 minutes
Released:
Mar 3, 2023
Format:
Podcast episode

Description

In a special 3-part season premiere, Halteres Presents is spotlighting tuberculosis diagnostics worldwide, and where things stand in the field today. In Part Two, Rich Thayer and Mickey Urdea are interviewing Dr. Peter Small, the Chief Medical Officer at Hyfe.ai, an acoustic epidemiology company which uses machine learning to build acoustic tools for respiratory diagnostics and monitoring. For more than a decade, Dr. Small was responsible for building and running the innovative TB program at the Bill & Melinda Gates Foundation, performing seminal work on clinical, epidemiologic, evolutionary, and genetic aspects of tuberculosis. He has deep expertise in translating cutting-edge science into drugs, diagnostic methods, and vaccines, as well as the business and public health processes to get innovative tools to those in need. Dr. Small holds a BA from Princeton University and a MD from the University of Florida, and he is also the Founding Director of the Stony Brook University Global Health Institute.
Released:
Mar 3, 2023
Format:
Podcast episode

Titles in the series (21)

Halteres Presents is a brand-agnostic interview podcast designed to unbiasedly highlight the happenings within the diagnostics industry. In each episode, founding partner Mickey Urdea and managing partner Rich Thayer interview an expert who brings their own unique perspective to an industry topic. Halteres Associates is a leading bioscience consultancy with extensive, long-term, direct operating experience in a broad spectrum of areas of expertise, including the development and commercialization of diagnostics, medical devices, therapeutics, research reagents, and bioscience tools.